Central African Republic
Tuberculosis profile
| High HIV burden |
Population  2013 4.6 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (1.5–3.4) 49 (33–74)
Mortality (HIV+TB only) 2.8 (2–3.7) 61 (44–79)
Prevalence  (includes HIV+TB) 20 (11–31) 422 (231–670)
Incidence  (includes HIV+TB) 17 (15–19) 359 (323–408)
Incidence (HIV+TB only) 6.9 (4–7.9) 150 (87–172)
Case detection, all forms (%) 52 (46–58)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.4 (0–2.5) 18 (7–36)
MDR-TB cases among notified pulmonary
TB cases
27 (0–170) 110 (43–220)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 454   361
Pulmonary, clinically diagnosed 2 360   0
Extrapulmonary 1 415   0
       
Total new and relapse 8 590    
Previously treated, excluding relapses 258    
Total cases notified 8 848    
Among 4 196 new cases:
147 (4%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 58 (9%) 58
Laboratory-confirmed RR-/MDR-TB cases     20
Patients started on MDR-TB treatment     20
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 978 (45)
HIV-positive TB patients 1 597 (40)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 184  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 68
Previously treated cases registered in 2012 60
HIV-positive TB cases, all types, registered in 2012 65
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 4.6
% Funded domestically 3%
% Funded internationally 49%
% Unfunded 48%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-26 Data: www.who.int/tb/data